ContraFect Stock Price

-0.029 (-28.97%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 38,050,956
Bid Price 0.0711
Ask Price 0.0725
News (1)
Day High 0.1005


52 Week Range


Day Low 0.091
Company Name Stock Ticker Symbol Market Type
ContraFect Corporation CFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.029 -28.97% 0.0711 19:59:55
Open Price Low Price High Price Close Price Prev Close
0.095 0.091 0.1005 0.0921 0.1001
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,950 38,050,956 $ 0.0940475 $ 3,578,597 - 0.083 - 4.54
Last Trade Time Type Quantity Stock Price Currency
19:59:55 formt 45,120 $ 0.0711 USD


Draw Mode:

ContraFect Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.11M 43.68M 43.64M $ - $ - -0.56 -0.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 3.70%

more financials information »

ContraFect News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.09070.12020.0830.101627849,905,297-0.0196-21.61%
1 Month0.09420.12020.0830.101520517,697,042-0.0231-24.52%
3 Months0.17510.1970.0830.10733896,818,611-0.104-59.39%
6 Months0.36970.36970.0830.14280123,933,127-0.2986-80.77%
1 Year2.374.540.0830.26068042,246,473-2.30-97.0%
3 Years1.0713.250.0831.45985,058-0.9989-93.36%
5 Years1.1613.250.0831.26840,466-1.09-93.87%

ContraFect Description

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 02:07:30